세계의 혈전 관리 디바이스 시장 : 인사이트, 경쟁 구도, 시장 예측(2032년)

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increasing prevalence of lifestyle disorders such as diabetes and hypertension, and increased in product developmental activities across the globe.

The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032. The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

Clot Management Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally in which approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.

The rising incidence of cardiovascular diseases (CVDs), such as heart attacks, strokes, and peripheral artery disease, significantly boosts the market for clot management devices. These conditions are often associated with the formation of blood clots, which can lead to life-threatening complications if not treated promptly. Clot management devices, including mechanical thrombectomy systems and catheter-directed thrombolysis, provide minimally invasive options for removing or dissolving clots, improving patient outcomes and reducing the need for complex surgeries thereby escalating the market growth across the globe.

Additionally, according to the recent update provided by the International Diabetes Federation, in 2021, approximately 537 million adults aged 20-79 were living with diabetes. This number was projected to rise to 643 million by 2030 and 783 million by 2045.

Additionally, as per the recent data provided by the IDF Diabetes Atlas, in 2022, out of the 8.75 million people living with type 1 diabetes worldwide, 1.52 million were under 20 years old. Additionally, 62% of all new type 1 diabetes cases in 2022 occurred in people aged 20 years or older. The increasing prevalence of diabetes is driving the demand for clot management devices, as diabetes significantly raises the risk of vascular complications, including blood clot formation. This elevated risk necessitates advanced clot management solutions such as thrombectomy devices, catheter-directed thrombolysis, and other minimally invasive procedures designed to quickly dissolve or remove clots, improving blood flow and reducing complications and thereby boosting the overall market of clot management devices across the globe.

Additionally, companies are amplifying their production of clot management devices and gaining approvals for the new products, thereby strategically expanding their market presence and driving further growth. For instance, in March 2025, Imperative Care, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its SymphonyTM 16F Catheter, the company's latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of the legs or abdomen that can have a life-threatening impact if left untreated.

However, the increased number of product recalls and the risk of complications associated with clot management devices such as bleeding, vessel damage, or infection may hinder the future market of clot management devices.

Clot Management Devices Market Segment Analysis:

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the clot management market, the stent retrievers category is expected to hold the largest share in the year 2024. This can be ascribed to their advantages such as mechanical thrombectomy with stent retrievers is reported to produce superior clinical outcomes in acute stroke patients compared to medical therapy alone. In addition to that, stent retrievers have a safety profile similar to that of systemic thrombolytic therapy. These devices are designed to mechanically remove blood clots from blocked arteries in the brain, thereby restoring blood flow quickly and effectively often within the critical window for preventing long-term neurological damage.

Moreover, improvements in product design such as the incorporation of platinum for improved visibility (Trevo Provue and Solitaire Platinum) and longer lengths up to 40 mm have helped in improving the first-pass reperfusion outcomes. The entry of recoverable self-expanding thrombectomy devices further offers advantages such as the devices restore flow immediately and avoid the placement of a permanent stent, immediate restoration of blood, and eliminating the need for the placement of a permanent stent thereby reducing the chances of in-stent restenosis. Stent retrievers offer superior outcomes compared to traditional thrombolytic drug therapy alone, including higher rates of recanalization, improved functional recovery, and reduced mortality. This has led to their inclusion in major stroke treatment guidelines and accelerated adoption across hospitals and stroke centers globally. Furthermore, technological innovations such as next-generation stent retrievers with enhanced radial force, better clot integration, and improved navigability are further expanding their clinical utility.

In addition, new product launches are also likely to upsurge the global stent retrievers market during the forecasted period. For instance, in August 2024, Gravity Medical Technology announced the launch of its next-generation stroke treatment devices the Neutron aspiration catheter and the Supernova stent retriever. The Supernova stent retriever's innovative design enhances the capture and removal of hard fibrin-rich (white) clots, which tend to present more in non-Caucasian populations.

Therefore, owing to the above-mentioned factors, the stent retriever's category is expected to generate considerable revenue thereby pushing the overall growth of the global clot management devices market during the forecast period.

North America is expected to dominate the overall clot management devices market:

North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

According, to recent data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults were diagnosed with coronary heart disease. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

The rising prevalence of coronary heart disease (CHD) significantly boosts the market for clot management devices. As CHD often leads to the formation of blood clots in coronary arteries, there is an increased demand for effective treatments to restore blood flow and prevent heart attacks. Clot management devices, such as thrombectomy and embolization systems, are essential in managing these conditions, driving their adoption in hospitals and emergency care settings.

Additionally, according to the latest report provided by the Centre for Disease Control and Prevention (2024), estimates indicated that 38.4 million people of all ages, or 11.6% of the U.S. population, had diabetes. Additionally, approximately, 38.1 million individuals aged 18 years and older, representing 14.7% of all U.S. adults, were affected by diabetes. Diabetes often leads to complications such as peripheral artery disease and deep vein thrombosis, where blood clots can block vessels and impair circulation. This rising need for effective clot prevention and treatment in diabetic populations is boosting the adoption of clot management devices, including thrombectomy and catheter systems, in both hospital and outpatient settings thereby escalating the overall market across the region.

Furthermore, one of the key reasons positively influencing the growth of the United States clot management devices market is the rising prevalence of cancers in the US population. As per the latest data provided by GLOBOCAN, in 2022, the estimated new cases of cancer in North America was 2.67 million and the projections were subjected to an increase of 3.83 million by 2045. Cancer patients are thought to have specific abnormal coagulation factors which increase the chances of thrombus formation. Additionally, chemotherapy is also related to the increased risk of venous thrombosis resulting in deep vein thrombosis. Therefore, the rising prevalence of cancers in the country is expected to aid in the growing need for thrombus management devices thereby resulting in an increase in product demand and aiding in the growth of the North America clot management devices market.

In addition, the increased strategic activities by the key market players are also likely to upsurge the clot management devices market across the region during the forecasted period. For instance, in June 2023, Penumbra, Inc., a global healthcare company, received FDA clearance and launched Lightning Bolt(TM) 7, an advanced arterial thrombectomy system. The device introduced modulated aspiration by combining Lightning Intelligent Aspiration technology with a microprocessor algorithm. It was designed to quickly remove large, fibrous arterial clots with minimal blood loss, targeting conditions like acute limb ischemia (ALI), hibernating thrombus, and visceral occlusions.

Therefore, the above-mentioned factors are expected to bolster the growth of the clot management devices market in North America during the forecast period.

Clot Management Devices Market Key Players:

Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

Recent Developmental Activities in the Clot Management Devices Market:

• In April 2024, Penumbra Inc. launched Lightning Flash 2.0 - the latest CAVT technology designed to rapidly remove blood clots
• In February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, announced the launch of the CEREGLIDE(TM) 71 Intermediate Catheter, designed for revascularization in acute ischemic stroke patients. This next-generation catheter, part of the CEREGLIDE family, was optimized for direct aspiration and delivering stent retrievers like the EMBOTRAP(TM) III Revascularization Device into the neurovasculature.

Key takeaways from the clot management devices market report study:

• Market size analysis for current clot management devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the clot management devices market.
• Various opportunities available for the other competitors in the clot management devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current clot management devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for clot management devices market growth in the coming future?

Target audience who can benefit from this clot management devices market report study:

• Clot management devices product providers
• Research organizations and consulting companies
• Clot management devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in clot management devices
• Various end-users who want to know more about the clot management devices market and the latest technological developments in the clot management devices market.

Frequently Asked Questions for the Clot Management Devices Market:

1. What are clot management devices?

• Clot management devices are medical devices that are employed in the removal of blood clots from peripheral as well as neurovasculature.

2. What is the market for clot management devices?

• The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032.

3. What are the drivers for the clot management devices market?

• The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the clot management devices market?

• Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

5. Which region has the highest share in the clot management devices market?

• North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

Table of Contents

1. Clot Management Devices Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Clot Management Devices Market Executive Summary

• 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1 The United States
• 4.2 Europe
• 4.3 Japan
• 4.4 China

5. Clot Management Devices Market Key Factors Analysis

• 5.1. Clot Management Devices Market Drivers
  • 5.1.1 The rising prevalence of cardiovascular diseases
  • 5.1.2 Increasing prevalence of lifestyle disorders such as diabetes and hypertension
  • 5.1.3 Increased product developmental activities across the globe.
• 5.2 Clot Management Devices Market Restraints and Challenges
  • 5.2.1 Increased number of product recalls
  • 5.2.2 The risk of complications associated with the devices
• 5.3 Clot Management Devices Market Opportunities
  • 5.3.1 Integration of artificial intelligence

6. Clot Management Devices Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Clot Management Devices Market Assessment

• 7.1 By Product Type
  • 7.1.1 Thrombectomy Devices
    • 7.1.1.1 Catheter-Directed Thrombolysis Devices
    • 7.1.1.2 Aspiration Devices
    • 7.1.1.3 Stent Retrievers
  • 7.1.2 Embelecotomy Catheters
  • 7.1.3 Inferior Vena Cava Filters
    • 7.1.3.1 Retrievable
    • 7.1.3.2 Permanent
  • 7.1.4 Compression Garments
  • 7.1.5 Others
• 7.2 By End-Users
  • 7.2.1 Hospitals
  • 7.2.2 Ambulatory Surgical Centers
  • 7.2.3 Homecare Settings
  • 7.2.4 Others
• 7.3 By Geography
  • 7.3.1 North America
    • 7.3.1.1 United States Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.1.2 Canada Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.1.3 Mexico Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.2 Europe
    • 7.3.2.1 France Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.2 Germany Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.3 United Kingdom Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.4 Italy Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.5 Spain Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2.6 Rest of Europe Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.3 Asia-Pacific
    • 7.3.3.1 China Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.2 Japan Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.3 India Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.4 Australia Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.5 South Korea Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3.6 Rest of Asia-Pacific Clot Management Devices Market Size in USD million (2022-2032)
  • 7.3.4 Rest of the World (RoW)
    • 7.3.4.1 Middle East Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4.2 Africa Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4.3 South America Clot Management Devices Market Size in USD million (2022-2032)

8. Clot Management Devices Market Company and Product Profiles

• 8.1 Edward LifeSciences Corporation
  • 8.1.1 Company Overview
  • 8.1.2 Company Snapshot
  • 8.1.3 Financial Overview
  • 8.1.4 Product Listing
  • 8.1.5 Entropy
• 8.2 Stryker
  • 8.2.1 Company Overview
  • 8.2.2 Company Snapshot
  • 8.2.3 Financial Overview
  • 8.2.4 Product Listing
  • 8.2.5 Entropy
• 8.3 Medical Device Business Services, Inc.
  • 8.3.1 Company Overview
  • 8.3.2 Company Snapshot
  • 8.3.3 Financial Overview
  • 8.3.4 Product Listing
  • 8.3.5 Entropy
• 8.4 Medtronic PLC
  • 8.4.1 Company Overview
  • 8.4.2 Company Snapshot
  • 8.4.3 Financial Overview
  • 8.4.4 Product Listing
  • 8.4.5 Entropy
• 8.5 Penumbra
  • 8.5.1 Company Overview
  • 8.5.2 Company Snapshot
  • 8.5.3 Financial Overview
  • 8.5.4 Product Listing
  • 8.5.5 Entropy
• 8.6 Microvention Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Company Snapshot
  • 8.6.3 Financial Overview
  • 8.6.4 Product Listing
  • 8.6.5 Entropy
• 8.7 Terumo Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Company Snapshot
  • 8.7.3 Financial Overview
  • 8.7.4 Product Listing
  • 8.7.5 Entropy
• 8.8 Boston Scientific Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Company Snapshot
  • 8.8.3 Financial Overview
  • 8.8.4 Product Listing
  • 8.8.5 Entropy
• 8.9 Abbott
  • 8.9.1 Company Overview
  • 8.9.2 Company Snapshot
  • 8.9.3 Financial Overview
  • 8.9.4 Product Listing
  • 8.9.5 Entropy
• 8.10. Acandis GmbH
  • 8.10.1 Company Overview
  • 8.10.2 Company Snapshot
  • 8.10.3 Financial Overview
  • 8.10.4 Product Listing
  • 8.10.5 Entropy
• 8.11. Perflow Medical Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Company Snapshot
  • 8.11.3 Financial Overview
  • 8.11.4 Product Listing
  • 8.11.5 Entropy
• 8.12. Koninklijke Philips N.V.
  • 8.12.1 Company Overview
  • 8.12.2 Company Snapshot
  • 8.12.3 Financial Overview
  • 8.12.4 Product Listing
  • 8.12.5 Entropy
• 8.13. phenox GmbH
  • 8.13.1 Company Overview
  • 8.13.2 Company Snapshot
  • 8.13.3 Financial Overview
  • 8.13.4 Product Listing
  • 8.13.5 Entropy
• 8.14. AngioDynamics
  • 8.14.1 Company Overview
  • 8.14.2 Company Snapshot
  • 8.14.3 Financial Overview
  • 8.14.4 Product Listing
  • 8.14.5 Entropy
• 8.15. ARGON MEDICAL
  • 8.15.1 Company Overview
  • 8.15.2 Company Snapshot
  • 8.15.3 Financial Overview
  • 8.15.4 Product Listing
  • 8.15.5 Entropy
• 8.16. BD
  • 8.16.1 Company Overview
  • 8.16.2 Company Snapshot
  • 8.16.3 Financial Overview
  • 8.16.4 Product Listing
  • 8.16.5 Entropy
• 8.17. B. Braun Melsungen AG
  • 8.17.1 Company Overview
  • 8.17.2 Company Snapshot
  • 8.17.3 Financial Overview
  • 8.17.4 Product Listing
  • 8.17.5 Entropy
• 8.18. Cardinal Health
  • 8.18.1 Company Overview
  • 8.18.2 Company Snapshot
  • 8.18.3 Financial Overview
  • 8.18.4 Product Listing
  • 8.18.5 Entropy
• 8.19. Braile Biomedica
  • 8.19.1 Company Overview
  • 8.19.2 Company Snapshot
  • 8.19.3 Financial Overview
  • 8.19.4 Product Listing
  • 8.19.5 Entropy
• 8.20. Cook
  • 8.20.1 Company Overview
  • 8.20.2 Company Snapshot
  • 8.20.3 Financial Overview
  • 8.20.4 Product Listing
  • 8.20.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us